Obesity Treatments

GLP-1 Drugs Drug Development Wegovy Market Competition Weight Loss Drugs Clinical Trials Medications Market Dynamics Biotech Companies Oral Therapies Diabetes Treatments Manufacturing Weight Loss Medications Eli Lilly Patient Affordability Weight Loss Medicines GLP-1 Medications Next-Generation Drugs

6 ARTICLES

2mo ago

Lilly Posts Blowout Quarter as Global GLP‑1 Push Tests Price‑for‑Volume Strategy

Expanded payer coverage, oral Foundayo filings and positive retatrutide trials put pressure on international launches to convert higher patient volume into sustained revenue.

3 ARTICLES

3mo ago

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Obesity Treatments

Lilly Posts Blowout Quarter as Global GLP‑1 Push Tests Price‑for‑Volume Strategy

Analysts Lift Eli Lilly Price Targets as Medicare Expands Low‑Cost GLP‑1 Access

UK Clears Oral Wegovy and Foundation Pledges Europe Research Cash

Kailera Leaps 62% in Nasdaq Debut After $625 Million IPO

HSBC Cuts Eli Lilly to Reduce, Lowers Target to $850 on GLP-1 Reset

Eli Lilly Jumps on GLP‑1 Momentum as 2026 Outlook Beats and Targets Rise

Eli Lilly Shifts to Access-First Strategy on GLP-1 Strength

Lilly's Rally Deepens as U.S. Access Deal Recasts Outlook for GLP‑1 Drugs

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws